Insider trade report
Open the filing on sec.gov
Anixa Biosciences, Inc. (ANIX)
Nasdaq: ANIX · Pharmaceutical Preparations · San Jose, CA · filing with the SEC since 1995
The companyfiscal 2024, as filed
Revenue$210,0000.0%
Net incomen/a
Earnings per share$-0.39-21.9%
Operating cash flow-$7.3M-18.1%
Cash$1.3M+38.9%
Debtn/a
Shareholders’ equity$20.0M-17.8%
Shares, diluted31.9M+3.0%
Return on equity-72.1%
The recordfrom its filings
Filings in 202636
Newest filingNov 2 · 4
Annual reportJan 12, 2026
Quarterly reportSep 9, 2026
Next report due10-K by Jan 29
Insider sales, 12 months$0.00
Insider buys, 12 months$500,000
Patents granted114
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jul 2026Net income -$10.4MCash from operations -$7.4Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.